nVerses Capital’s Boston Scientific BSX Stock Holding History

nVerses Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,613	Closed	-$352K	–	320
2026 Q1	$352K	Buy	+5,613	New	+$449K	0.32%	124

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

nVerses Capital's BSX Position: Q2 2026 in Review

nVerses Capital sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 5,613 shares — an estimated $352K sold.

nVerses Capital first reported a position in BSX in Q1 2026 and held it in 1 quarter. The position peaked at $352K in Q1 2026. 1,213 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

nVerses Capital reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
nVerses Capital sold 5,613 Boston Scientific shares in Q2 2026, an estimated $352K.
nVerses Capital first reported a position in Boston Scientific in Q1 2026 and held it in 1 quarter.
nVerses Capital's Boston Scientific position peaked at $352K in Q1 2026.
1,213 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.